IP Library Granted Patent US 46,897
Granted Patent E1
US 46,897 · App. 15/203,550 · Granted Jun 19, 2018

Recombinant cell clones having increased stability and methods of making and using the same

Inventors: Manfred Reiter (Vienna, AT); Wolfgang Mundt (Vienna, AT); Friedrich Dorner (Vienna, AT)
Assignees: Baxalta Incorporated; Baxalta GmbH
C12N5/0075C12N5/0043C12N2500/32C12N2500/38C12N2500/46C12N2500/50C12N2500/76C12N2531/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 46,897
App. No.
15/203,550
Granted
Jun 19, 2018
Kind
E1
Abstract

Disclosed are a stable recombinant cell clones which are stable in serum- and protein-free medium for at least 40 generations, a biomass obtained by multiplying the stable cell clone under serum- and protein-free culturing conditions, and a method of preparing recombinant proteins by means of the biomass. Furthermore, the invention relates to a method of recovering stable recombinant cell clones.

Claims (35)

1. A method for obtaining a stable recombinant mammalian cell clone that produces a recombinant product and is stable under production conditions in serum- and protein-free medium for at least 40 generations, the method comprising:

providing a recombinant original mammalian cell clone, wherein the recombinant original mammalian cell clone has a selection marker,

cultivating the recombinant original cell clone on serum-containing medium,

adapting the cells to serum- and protein-free medium with neither selection pressure for the selection marker nor selection for a polypeptide factor that replaces serum components,

testing the cell culture after adaptation for stable product-producers with neither selection pressure for the selection marker nor selection for a polypeptide factor that replaces serum components, and

cloning a stable product-producer-cell clone in serum- and protein-free conditions with neither selection pressure for the selection marker nor selection for a polypeptide factor that replaces serum components.

2. The method according to claim 1 , wherein the stable product-producer cell clone obtained is present in isolated form after the step of cloning.

3. The method according to claim 1 , wherein the recombinant cell clone comprises a nucleic acid encoding a recombinant polypeptide or protein.

4. The method according to claim 1 , wherein the recombinant product is Factor VIII.

5. The method according to claim 1 , wherein the recombinant product is Factor IX.

6. The method according to claim 1 , wherein the recombinant product is Factor VII.

7. The method according to claim 1 , wherein the recombinant product is von Willebrand factor (vWF).

8. The method according to claim 1 , wherein the original mammalian cell clone is a CHO cell clone.

9. A stable product-producer-cell clone that produces a recombinant product obtained by the method comprising:

providing a recombinant original mammalian cell clone, wherein the recombinant original mammalian cell clone has a selection marker and an amplification marker,

cultivating the recombinant original cell clone on serum-containing medium to create a cell culture,

adapting the cell culture to serum- and protein-free medium with neither selection pressure for the selection marker nor selection pressure for the amplification marker,

testing the cell culture after adaptation for stable product-producers with neither selection pressure for the selection marker nor selection pressure for the amplification marker, and

isolating a stable product-producer-cell clone in serum- and protein-free conditions with neither selection pressure for the selection marker nor selection pressure for the amplification marker.

10. The stable product-producer-cell clone according to claim 9, wherein the recombinant product is Factor VIII.

11. The stable product-producer-cell clone according to claim 9, wherein the recombinant product is Factor IX.

12. The stable product-producer-cell clone according to claim 9, wherein the recombinant product is Factor VII.

13. The stable product-producer-cell clone according to claim 9, wherein the recombinant product is von Willebrand factor (vWF).

14. The stable product-producer-cell clone according to claim 9, wherein the stable recombinant mammalian cell clone is a CHO cell clone.

15. A cell culture comprising a stable product-producer-cell clone that produces a recombinant product, wherein the cell clone is obtained by the method comprising:

providing a recombinant original mammalian cell clone, wherein the recombinant original mammalian cell clone has a selection marker and an amplification marker,

cultivating the recombinant original cell clone on serum-containing medium to create a cell culture,

adapting the cell culture to serum- and protein-free medium with neither selection pressure for the selection marker nor selection pressure for the amplification marker,

testing the cell culture after adaptation for stable product-producers with neither selection pressure for the selection marker nor selection pressure for the amplification marker,

isolating a stable product-producer-cell clone in serum- and protein-free conditions with neither selection pressure for the selection marker nor selection pressure for the amplification marker, and

culturing the stable product-producer-cell clone in a cell culture free of serum- or protein-containing additives of human or animal origin.

16. The cell culture according to claim 15, wherein the recombinant product is Factor VIII.

17. The cell culture according to claim 15, wherein the recombinant product is Factor IX.

18. The cell culture according to claim 15, wherein the recombinant product is Factor VII.

19. The cell culture according to claim 15, wherein the recombinant product is von Willebrand factor (vWF).

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 4, 2016
From: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE SA
To: BAXALTA INCORPORATED; BAXALTA GMBH
Reel/Frame 040231/0990 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 4, 2016
From: BAXTER INNOVATIONS GMBH
To: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE SA
Reel/Frame 040567/0848 →
CHANGE OF NAME Recorded Nov 4, 2016
From: BAXTER AKTIENGESELLSCHAFT
To: BAXTER EASTERN EUROPE VERTRIEBS GMBH
Reel/Frame 040569/0383 →
CHANGE OF NAME Recorded Nov 4, 2016
From: BAXTER EASTERN EUROPE VERTRIEBS GMBH
To: BAXTER TRADING GMBH
Reel/Frame 040569/0387 →
CHANGE OF NAME Recorded Nov 4, 2016
From: BAXTER TRADING GMBH
To: BAXTER INNOVATIONS GMBH
Reel/Frame 040569/0391 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 27, 2016
From: REITER, MANFRED; MUNDT, WOLFGANG; DORNER, FRIEDRICH
To: BAXTER AKTIENGESELLSCHAFT
Reel/Frame 040155/0171 →
Priority Claims (1)
AT 1073/97 · Jun 20, 1997 · national
Continuity (9)
Reissue 12986111 · Jan 6, 2011
Division 14567942 · Dec 11, 2014
Reissue 12986111 · Jan 6, 2011
Continuation 12488441 · Jun 19, 2009
Continuation 11482504 · Jul 7, 2006
Division 11123362 · May 6, 2005
Continuation 10170661 · Jun 12, 2002
Continuation 09324612 · Jun 2, 1999
Continuation In Part 09100253 · Jun 19, 1998